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Abstract: Fludarabine (FAMP) is the most effective and most extensively studied purine 
analog in indolent B-cell malignancies. Its use is indicated for ﬁ  rst- and second-line treatment of 
B-cell chronic lymphocytic leukemia (B-CLL). FAMP as a single agent has produced superior 
response rates and progression-free survival than standard therapy with chlorambucil and 
alkylator-based regimen. Efﬁ  cacy of FAMP may be increased by combining this purine analog 
with other chemotherapeutic and non-chemotherapeutic agents. FAMP and cyclophosphamide 
combination (FC) has shown promising results with higher overall response and complete 
response rates than FAMP in monotherapy, although no difference has been detected in survival. 
Quality of response and eradication of minimal residual disease (MRD) have been reported to 
be associated with prolonged survival. Eradication of MRD has been achieved by combining 
FC with mitoxantrone or monoclonal antibody including alemtuzumab or rituximab or both. 
FAMP has been widely used in non-myeloablative conditioning regimens, often combined with 
a variety of other cytotoxic agents, with the aim of inducing enough immunosuppression to 
allow successful engraftment and to exert some pretransplant anti-tumor activity. The current 
paper provides an overview of use of FAMP as a single agent or as a cornerstone of different 
therapeutic strategies for treatment of B-CLL patients.
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Introduction
B-cell chronic lymphocytic leukemia (B-CLL) is the most common hematological 
malignancy in the western world. For several decades the standard treatment for this 
disease has been chlorambucil (CHL) or cyclophosphamide (CTX), alone or combined 
with corticosteroids, but complete remissions have been rare with these agents. Other 
alkylator-based regimens including CVP (CTX, vincristine, prednisone) or CHOP 
(CTX, doxorubicin, vincristine, prednisone) have been reported to have a compa-
rable efﬁ  cacy in terms of response and survival.1 Since the late 1980s the success of 
cytarabine (ara-C) in the treatment of patients with leukemia and lymphoma has gen-
erated interest in other nucleoside analogs. Fludarabine (FAMP), cladribine (2CdA) 
and pentostatin (DCF) are three chemotherapeutic agents belonging to the family of 
purine analogs and displaying remarkable activity in malignancies arising from the 
clonal expansion of lymphocytes, and particularly in B-CLL. These three agents have 
similar chemical structures and mechanisms of action such as induction of apoptosis. 
However, they also have signiﬁ  cant differences, especially in their interactions with 
enzymes involved in adenosine and deoxyadenosine metabolism. Different studies 
suggest that FAMP and 2CdA have similar activity in B-CLL while DCF used alone 
seems to be less active in this disease.
The most extensively studied of these purine analogs in indolent B-cell malig-
nancies is FAMP. Alone, as well as in combination with DNA-damaging drugs or 
membrane-targeted antibody, FAMP has a particularly well known efﬁ  cacy in the 
treatment of B-CLL.Therapeutics and Clinical Risk Management 2009:5 188
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The current review brings together knowledge of the 
pharmacokinetics, mechanisms of action and clinical use of 
FAMP in B-CLL.
Pharmacokinetics
FAMP is negatively charged at physiological pH and is 
therefore unable to enter cells. Thus, it functions as a pro-
drug that is converted metabolically by dephosphorylation 
to the antimetabolite, F-ara-A.
F-ara-A appears to be taken into cells by facilitated 
transport2 where it is rephosphorylated to the monophosphate 
by deoxycytidine kinase and subsequently to the diphos-
phate and triphosphate.3–5 The triphosphate, F-ara-ATP, is 
the major intracellular metabolite of FAMP and the only 
metabolite known to have cytotoxic activity. The relatively 
low concentrations of ﬂ  udarabine mono- and diphosphate 
in cells suggests that the activity of deoxycytidine kinase 
is rate-limiting for triphosphate formation.6 Several in vitro 
investigations focused on the relationship between the dose 
rate of FAMP, the F-ara-A concentrations in plasma, and the 
cellular accumulation of F-ara-ATP.
The standard infusion rate for treatment of B-CLL, 
25 or 30 mg/m2 of FAMP infused over 30 min, results in 
Cmax values for F-ara-A that reach 3 to 5 μmol/L at the end 
of the infusion.7,8
Serial sampling of leukemia cells from patients receiving 
these standard doses of FAMP has demonstrated that the peak 
concentrations of F-ara-ATP are achieved 4 hours after start 
of drug infusion.7–11
The peak F-ara-ATP concentration appeared somewhat 
later in patients who received doses of 100 to 125 mg/m2, 
suggesting that higher plasma F-ara-A concentrations would 
support linear accumulation for longer periods.7
Although there was heterogeneity among individuals for 
the rate of F-ara-ATP accumulation, the peak concentrations 
were clearly proportional to the dose of FAMP infused.
The retention of F-ara-ATP was also variable among 
individuals. Elimination was generally monophasic, but the 
half-life in B-CLL cells ranged from a few hours to several 
days with a median value of 15 hours.11 Thus, F-ara-ATP 
is a relatively long-lived active metabolite, a characteristic 
that probably accounts for the observed efﬁ  cacy of daily 
administration schedules.12,13
The constancy of the cellular pharmacokinetics of 
F-ara-ATP in an individual and the heterogeneity in this 
parameter among patients suggested the possibility that 
F-ara-ATP cellular pharmacology might be associated with 
clinical response to FAMP therapy. No correlation was 
observed, however, between response and F-ara-ATP peak 
values, elimination rates and total cellular exposure after the 
ﬁ  rst FAMP injection.
Although FAMP is mostly used as an intravenous (iv) 
formulation 10 mg FAMP in an immediate release tablet 
has become available. The bioavailability of oral FAMP 
is approximately 51%–55% following single and multiple-
dose administration, with low intra-individual variation.14 
Systemic bioavailability, Cmax and time to Cmax are increased 
slightly with concomitant food intake; the terminal half-life 
is unaffected15 This, and other pharmacokinetic studies,16,17 
have shown that a once-daily oral FAMP dose of 40 mg/m2 
would provide a similar systemic exposure to ﬂ  udarabine 
25 mg/m2 iv.
Oral FAMP is typically given at a dosage of 40 mg/m2 
(7–8 tablets) once daily for 5 days, repeated every 4 weeks 
for up to 6 cycles.
Mechanism of action
Every demonstrable cytotoxic mechanism of action of 
fludarabine requires the presence of F-ara-ATP. The 
principal action of F-ara-ATP is in the inhibition of DNA 
synthesis.18,19
Several speciﬁ  c enzymes involved with DNA synthesis 
are targets for inhibition by F-ara-ATP.20 In particular, 
F-ara-ATP competes as an alternative substrate with the 
normal deoxynucleotide, deoxyadenosine 5’-triphosphate 
(dATP), inhibiting directly the DNA polymerases. Further-
more F-ara-ATP is able to inhibit DNA primase, an accessory 
protein that synthesizes an RNA primer required for initiation 
of lagging strand synthesis by DNA polymerase.21,22
F-ara-ATP is also an effective inhibitor of ribonucleotide 
reductase, resulting in lowering of cellular deoxynucleotide 
pools which are maintained by this enzyme.23–25 This would 
change the ratio of F-ara-ATP to dATP and consequently 
self-potentiates the DNA synthesis-directed actions of 
ﬂ  udarabine.
In addition, F-ara-AMP is incorporated into DNA, 
particularly at the 3’-terminus, as purine analog.26,27 This 
results in DNA ligase I inability to join it to an adjacent 
piece of DNA. Moreover, the free triphosphate interacts 
with this enzyme to block AMP binding and ligation of 
single strands.
These actions on DNA ligase I have important implications 
for the actions of the drug on the function of this enzyme in 
DNA replication and repair.
Together these actions are likely to result in complete 
inactivation of DNA synthesis followed by an initiation Therapeutics and Clinical Risk Management 2009:5 189
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of programmed cell death that ends in apoptosis of the 
cell.28–30
Moreover, F-ara-ATP can induce cell death in quiescent 
cells in the absence of its incorporation into DNA by the 
activation of the mitochondrial pathway of the apoptotic 
cascade.31
The mechanism of action of FAMP is reported in 
Figure 1.
FAMP in monotherapy
FAMP has been evaluated as monotherapy in several non 
comparative studies conducted in treated and untreated 
B-CLL patients and at the time it gives the highest response 
rate reported for a single agent in B-CLL.
One of the initial studies was conducted by Keating 
et al. This trial included 68 patients with refractory B-CLL 
who received FAMP as a single agent at 25 to 30 mg/m2/d 
for 5 days every 4 weeks. Authors described a complete 
response (CR) rate of 13% with an overall response (OR) 
rate of 57%. Median overall survival (OS) was 16 months. 
Toxicities included thrombocytopenia and neutropenia, with 
9% of patients experiencing major infections.32
The largest series of patients reporting FAMP activity 
in relapsed or refractory B-CLL has been reported by Sorensen 
et al Seven hundred and three patients were treated with 
25 mg/m2/d for 5 days every 4 weeks, achieving a complete 
response (CR) in 3% of cases with an OR rate of 32%. Median 
OS was 12.6 months. Major toxicities were hematologic in 43% 
of patients, infections in 22%, and neurotoxicity in 14%.33
Small-scale studies have also been conducted in treat-
ment-naïve patients. The initial study, involving 33 patients 
who were treated with FAMP (30 mg/m2/d for 5 days, 
repeated every 4 weeks), reported an OR rate of 79%, with 
33% of patients achieving a CR and a further 39% a CR 
with residual nodules as the only evidence of disease. The 
response was rapid, usually occurring after 3–6 courses of 
treatment.34
These ﬁ  ndings were conﬁ  rmed by subsequent studies 
with standard dose of FAMP which reported an OR rates of 
80% to 100%12,35,36 and a median time to disease progression 
of 33 months.12
As previously reported more recently an oral formulation 
of FAMP has been developed. Oral FAMP is indicated as 
second-line therapy in patients who have not responded to, 
or whose disease has progressed during or after treatment 
with, at least one standard alkylating agent-containing regi-
men. Recently, in most European countries oral FAMP has 
been licensed as ﬁ  rst-line treatment in B-CLL.
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DNA RNA
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Figure 1 Metabolism and mechanisms of actions of ﬂ  udarabine.
Abbreviations: A, adenosine; dA, deoxyadenosine; F-ara-A, 9-β-D-arabinosyl-2-ﬂ  uoroadenine; MP, DP, TP refer to nucleoside 5’-monophosphates, diphosphates and triphosphates, 
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In previously treated patients receiving oral FAMP 
monotherapy OR rates of 46% to 51% were achieved, 
depending on the response criteria used.37 Oral FAMP is 
also an effective ﬁ  rst-line treatment. Rossi et al conducted a 
multicenter open label study in 81 untreated B-CLL patients 
receiving oral FAMP 40 mg/m2/d for 5 days every 4 weeks for 
6 to 8 cycles. The OR rate was 71.6% (CR 37%) according to 
International Workshop on Chronic Lymphocytic Leucemia 
(IWCLL) criteria and 80.2% (CR 12.3%) using National 
Cancer Institute-Working Group (NCI) criteria. The OR was 
comparable with that achieved in a similar historical cohort 
who received ﬁ  rst-line therapy with iv FAMP.38
The next logical step was to compare FAMP with tradi-
tional alkylator-based therapies in B-CLL patients. Several 
phase III studies conducted in the USA and Europe have 
compared the efﬁ  cacy of iv FAMP as a single agent against 
that of CHL,39 CAP (CTX, doxorubicin, prednisone)40,41 and 
CHOP combination41 in previously untreated patients with 
Binet stage B and C B-CLL.
The pivotal phase III multicenter study conducted by US 
Intergroup39 compared iv FAMP (25 mg/m2/d for 5 days) to 
oral CHL (40 mg/m2/d for 1 day) and to the combination of 
the two drugs (iv FAMP 20 mg/m2/d for 5 days plus oral 
CHL (20 mg/m2/d for 1 day) as ﬁ  rst-line therapy. Patients 
failing initial therapy were allowed to cross over to the other 
drug.
FAMP-treated patients had signiﬁ  cantly higher OR and 
CR rates than those treated with CHL (63% vs 37% and 
20% vs 4% respectively). The median duration of response 
and the median progression free survival (PFS) in the 
FAMP group were signiﬁ  cantly longer than in CHL treated 
patients (25 vs 14 months and 20 vs 14 months respectively). 
However OS did not differ between the two different treat-
ments. The cross-over planned in this trial may play a role 
in these results considering that the response rate to CHL 
among FAMP failures was very low (7%) and the response 
rate to FAMP among CHL failures was signiﬁ  cantly higher 
(46%). Severe infections and neutropenia were more fre-
quent with FAMP than with CHL. Overall toxic effects 
were tolerable with the two single-drug regimens, while 
the combination arm was discontinued during the study 
because of the toxicity.
FAMP has been compared to CHL plus prednisone in 
an Italian phase III multicenter study. One hundred forty-
seven previously untreated patients with active B-CLL were 
randomized to receive iv FAMP (25 mg/m2/d for 5 days) or 
oral CHL (30 mg/m2 on days 1 and 15) plus intramuscular 
prednisone (40 mg/m2 on days 1–5 and 15–19). Treatment 
cycles were repeated every 4 weeks. FAMP was the more 
effective of the two treatments, resulting in a higher CR rate 
(47% vs 31%), although OR rates were similar in the two 
arms. The treatment response was more durable with FAMP 
than with CHL plus prednisone (28 vs 21 months).42
Recently the German CLL Study Group (GCLLSG) 
initiated a phase III study (CLL5 protocol) to evaluate the 
effect of FAMP versus CHL in ﬁ  rst line therapy of elderly 
patients with advanced CLL. Long-term follow-up analysis 
shows that elderly patients have no signiﬁ  cant clinical beneﬁ  t 
from ﬁ  rst-line therapy with FAMP in comparison to CHL. 
Though higher CR and OR rate FAMP failed to show any 
beneﬁ  t in terms of PFS and OS. A possible explanation for 
this phenomenon is the longer treatment period with CHL 
(0.4 mg/kg dose escalation up to 0.8 mg/kg every 15 day 
for up to 12 months), that might prevent earlier relapses. 
Moreover, in cases of relapse FAMP treated patients received 
either no treatment at all or more intense regimen in com-
parison to CHL.43
A French Cooperative Group phase III study40 com-
pared the effectiveness of fludarabine (25 mg/m2/d for 
5 days) with CAP regimen (CTX 750 mg/m2 iv on day 1, 
doxorubicin 50 mg/m2 iv on day 1, prednisone 40 mg/m2 
oral on days 1–5) in ﬁ  rst and second-line treatment. A total 
of 6 cycles at 28 day intervals were administered. Higher 
response rate to FAMP was observed in both untreated 
(71% vs 60%) and pre-treated (48% vs 27%) cases, although 
the difference was statistically signiﬁ  cant only in pre-treated 
cases. In the latter group, remission duration and survival 
did not differ between treatment groups. In untreated cases, 
on the other hand, ﬂ  udarabine induced signiﬁ  cantly longer 
remissions than CAP.
In a second French Cooperative Group study 938 treat-
ment-naive patients were randomized to receive FAMP, 
CAP or CHOP (vincristine 1 mg/m2 iv on day 1, doxoru-
bicin 25 mg/m2 iv on day 1, CTX 300 mg/m2 oral on days 
1–5, prednisone 40 mg/m2 iv oral on days 1–5) repeated 
every 4 weeks. The response rate was greater in patients 
treated with FAMP and CHOP compared to CAP. There was 
no difference in PFS and OS between the groups. Time of 
second-line therapy was signiﬁ  cantly longer in the FAMP 
group while the purine analog was better tolerated compared 
to CHOP and CAP. Consequently patients treated with 
ﬂ  udarabine enjoyed a better quality-adjusted time without 
symptoms or toxicity.41
Some investigators attempted to identify factors that 
predict a good response to FAMP. In an M.D. Anderson 
Cancer Center study of 264 pre-treated and untreated B-CLL Therapeutics and Clinical Risk Management 2009:5 191
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patients receiving FAMP and prednisone a multivariate 
analysis-derived prognostic model for response to treatment 
was proposed and 4 factors were found to be signiﬁ  cantly 
associated with worse response: Rai III-IV stage disease, prior 
therapy, older age, and low albumin levels.44
Dhöner et al studied mononuclear cells from 100 patients 
(90 B-CLL, 7 B-cell prolymphocytic leukemia, 3 Waldenström 
macroglobulinemia) using ﬂ  uorescence in situ hybridization 
(FISH) with a genomic p53 DNA probe. Seventeen of the 
100 patients exhibited a monoallelic p53 gene deletion by 
FISH. Fifty patients received therapy with purine analogs. 
The response to therapy depended strongly on the presence 
of a p53 gene deletion. None of the 12 patients with a dele-
tion responded to therapy with FAMP or pentostatin, while 
20 of 36 patients without a deletion who were assessable for 
response achieved a remission (p   0.001).The difference in 
survival probabilities from the time of diagnosis and from 
the start of treatment with purine analogs between the two 
groups was highly signiﬁ  cant (p   0.001). In multivariate 
analysis, p53 gene deletion was the strongest prognostic 
factor for survival. In conclusion, p53 gene deletion predicts 
for non-response to therapy with purine analogs and for poor 
survival in B-CLL.45 More recently, Valgañón et al analyzed 
the aberrations in p53, including the methylation status of its 
promoter, in 54 patients with advanced stage B-CLL who 
received FAMP as ﬁ  rst-line. They conﬁ  rmed that the abnor-
malities of p53, either methylation or deletion, were associ-
ated with short survival and non-response to therapy.46
The experiences with FAMP in monotherapy are reported 
in Table 1.
FAMP in combination treatment
Efﬁ  cacy of FAMP may be increased combining this purine 
analog with other agents. Indeed, FAMP has been shown 
to have a biochemical modulating effect on other chemo-
therapeutic agents in vitro, for example CTX,47,48 ara-C49,50 
cisplatin51,52 and mitoxantrone.53,47 In view of this synergistic/
biochemical modulating effect, attempts to improve the CR 
and relapse rate have been explored with the use of FAMP 
in combination with other chemotherapeutic agents. Stud-
ies exploring efﬁ  cacy and safety FAMP-based schedule are 
listed in Tables 2, 3 and 4.
FAMP with alkylating agents
Taking into account the wide use of CHL in B-CLL the 
combination of FAMP plus CHL has been explored in 
clinical trials.54,55 This treatment did not show a signiﬁ  cant 
improvement in response rate or survival compared with 
FAMP alone. Furthermore, treatment with FAMP plus CHL 
appeared to be associated with a higher incidence of adverse 
events compared with either FAMP or CHL alone.
In particular in the CALGB study39 as previously 
mentioned, FAMP treatment was compared to CHL and 
to the combination of the two drugs as ﬁ  rst-line therapy. 
Assignment of patients to the FAMP plus CHL group was 
stopped when a planned interim analysis revealed excessive 
toxicity and a response rate that was not better than the rate 
with FAMP alone.39,56
FAMP and CTX is by far the best investigated 
FAMP- combination. It has been examined in several trials, 
including trials with additional ﬁ  lgrastim support and with 
mitoxantrone added to the regimen.
One of the ﬁ  rst non-comparative studies was conducted 
by O’Brien et al in 128 untreated and pre-treated patients 
with B-CLL who received FAMP 30 mg/m2/d iv for 3 days 
and CTX at either 500 mg/m2/d for 3 days, 350 mg/m2/d 
for 3 days, or 300 mg/m2/d for 3 days. The CTX dose was 
decreased because of myelosuppression in the early part of 
the study. Patients were stratiﬁ  ed into four groups according 
to pretreatment status, that is untreated, treated with alkyl-
ating agents, treated with and responsive to FAMP with or 
without alkylating agents but relapsing, and treated with and 
refractory to FAMP with or without alkylating agents.
The OR and the CR rates were 88% and 35% respectively 
for previously untreated patients, compared with 85% and 
15% in patients previously treated with alkylating agents. 
In the subgroup of patients refractory to FAMP, an OR rate 
of 39% suggests that the combination of FAMP with CTX 
may be synergistic in this group. The median time to progres-
sion was 12 to 38 months in patients who had received prior 
therapy. In previously untreated patients, the median time to 
progression and survival duration had not been reached after 
a median follow-up of 41 months.57
Similar results in terms of OR and CR rates were reported 
in a smaller study conducted in treatment-naïve patients by 
Flinn et al. In this study combination of FAMP and CTX were 
investigated with the ﬁ  lgrastim support FAMP 20 mg/m2/d iv 
for 5 days and CTX 600 mg/m2/d iv on day 1 were followed 
by ﬁ  lgrastim 5 μg/kg for 10–14 days starting around day 8. 
Treatment was repeated every 28 days for a maximum of six 
cycles. An interesting ﬁ  nding was the reduced incidence of 
leukocytopenia, and the increased incidence of thrombocy-
topenia and anemia in patients receiving G-CSF in addition 
to the FAMP plus CTX combination.58
FAMP associated to CTX has also been investigated in 
3 recently published comparative studies.Therapeutics and Clinical Risk Management 2009:5 192
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Fludarabine for chronic lymphocytic leukemia
In the first comparative phase III trial, GCLLSG 
CLL4 study, 362 treatment-naïve patients with advanced 
B-CLL, were randomly assigned to receive either FAMP 
(25 mg/m2/d for 5 days iv, repeated every 28 days) or 
FC combination therapy (FAMP 30 mg/m2/d plus CTX 
250 mg/m2/d for 3 days iv, repeated every 28 days). Both regi-
mens were administered up to a maximum of 6 courses.
Patients receiving FC combination chemotherapy showed 
a signiﬁ  cantly higher CR rate (24%) and OR rate (94%) com-
pared with FAMP alone (7% and 83%). FC treatment also 
resulted in longer median PFS (48 vs 20 months) and longer 
treatment-free survival (37 vs 25 months). At the time of writ-
ing, no difference in median OS has been observed. FC caused 
signiﬁ  cantly more thrombocytopenia and leukocytopenia but 
did not increase the number of severe infections.59 No signiﬁ  -
cant difference was detected in health-related quality of life 
between FAMP and FC-treated patients.43 In a recent update of 
the outcome of patients enrolled in the CLL4 GCLLSG trial the 
analysis according to clinical and biologic parameters has been 
presented. Investigating a speciﬁ  c treatment effect PFS was 
longer after FC for the following subgroups: unmutated immu-
noglobulin heavy chain (IgVH) gene, no aberration, del(11q), 
unmutated TP53, CD38   7%, and beta2microglobulin 
 5 mg/L. OS was signiﬁ  cantly longer after FC only in the 
subgroups with 11q-, +12, and unmutated TP53. However, in 
comprehensive multivariate analysis of TP53 mutations, del 
(11q), thymidine kinase  10 remained a predictor for PFS 
and OS independently of the improvement by FC.60
Results of a second comparative study were reported by 
Flinn et al. This is a phase III randomized Intergroup trial 
comparing FC regimen versus FAMP alone in 278 patients 
receiving their ﬁ  rst chemotherapy regimen for B-CLL. Dos-
ages of FC schedule were the same as the ﬁ  rst study. Authors 
conﬁ  rmed the superiority of FC arm in terms of OR (74.3% 
vs 59.5%), CR (23.4% vs 4.6%) and PFS (31.6 vs 19.2 
months). OS was not different between the two arms. Regard-
ing toxicity FAMP and CTX caused additional hematologic 
toxicity, including more severe thrombocytopenia, but it did 
not increase the number of severe infections.61
The third randomized study was published by Catovsky 
et al.62 Seven hundred and seventy-seven patients with previ-
ously untreated B-CLL requiring treatment were randomly 
assigned to FAMP (25 mg/m²/d iv or 40 mg/m²/d orally for 
5 days) or FC schedule (FAMP 25 mg/m²/d iv and CTX 
250 mg/m²/d iv for 3 days or orally over 5 days with FAMP 
24 mg/m²/d and CTX 150 mg/m²/d) for 6 courses, or CHL 
(10 mg/m²/d for 7 days) until maximum response or up to 
12 courses. Analysis was by intention to treat. There was 
no signiﬁ  cant difference in OS between patients given FC, 
FAMP or CHL. CR and OR rates were better with FC than 
with FAMP (CR 38% vs 15%, respectively; OR 94% vs 80%, 
respectively), which were in turn better than with CHL (CR 
7%, OR 72% respectively). PFS at 5 years was signiﬁ  cantly 
better with FC (36%) than with FAMP (10%) or CHL (10%). 
FC was the best combination for all ages, including patients 
older than 70 years, and in prognostic groups deﬁ  ned by 
IgVH gene mutation status and cytogenetics. Interestingly, 
the same PFS has been reported after FAMP alone and after 
CHL. The dose of CHL used in the LRFCLL4 trial was almost 
double that used by Rai et al in the earlier comparison,39 
suggesting that when a higher dose is used FAMP has no 
advantage over CHL.
A meta-analysis of these data and those of two published 
phase III trials showed a consistent beneﬁ  t for the FC regi-
men in terms of PFS.62
FC schedule was also investigated using FAMP and CTX 
as oral formulation.
Cazin et al reported in 75 treatment-naïve patients with 
B-CLL an OR and a CR rate of 75% and 53% respec-
tively, and a median PFS of 5 years, administering oral 
FAMP (30 mg/m2/d days 1–5) plus oral CTX (200 mg/m2/d 
days 1–5) every 28 days for 6 courses.63
Moreover, Laurenti et al tested the efﬁ  cacy and safety 
of oral FAMP and CTX as front-line therapy and assessed 
the inﬂ  uence of IgVH gene mutation status, interphase 
cytogenetic abnormalities, and expression of ZAP-70 and 
CD38 on clinical outcome. Treatment schedule consisted 
of oral FAMP (30 mg/m2) and oral CTX (250 mg/m2) 
for 3 consecutive days every 4 weeks for 6 cycles. High 
risk cytogenetic group was defined by the abnormality 
del(11q22.3) or del(17p13.1). Among the 35 evaluable 
patients, 14 (40%) obtained a CR and 13 (37%) a partial 
response (PR). The median PFS was 23 months and median 
time to re-treatment (TTR) was 38 months. A signiﬁ  cantly 
lower OR rate (43% vs 85%), a shorter PFS (22 vs 27 months), 
and a shorter TTR (22 vs 40 months) were noticed in the 
‘high risk’ cytogenetic abnormalities group; TTR was also 
shorter in IgVH-unmutated than in IgVH-mutated patients 
(26 vs 41 months).64
FAMP with anthracyclines 
or anthracenedione
The addition of mitoxantrone to FAMP did not markedly 
increase the response rate to FAMP, but the combination 
of FAMP with CTX and mitoxantrone (FCM) showed 
promising results. The efﬁ  cacy of two slightly different Therapeutics and Clinical Risk Management 2009:5 194
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Fludarabine for chronic lymphocytic leukemia
treatment regimens was assessed in a clinical trial in recurrent 
or resistant B-CLL patients.65 Twenty-three patients received 
iv FAMP 25 mg/m2 on days 1–3, CTX 600 mg/m2 on day 1 
and mitoxantrone 8 mg/m2 on day 1, at 4-week intervals 
for up to 6 courses. A further 37 patients received the same 
FAMP regimen plus CTX 200 mg/m2/d on days 1–3 and 
mitoxantrone 6 mg/m2 on day 1. The OR was 78%, including 
50% CR and 28% PR. Absence of minimal residual disease 
(MRD) was detected in 17% of patients by cytoﬂ  uorimetric 
and molecular methods. The median duration of response 
was 19 months and the actuarial median survival duration 
was 41 months. The incidence of myelosuppression and 
infection was noticeably higher in this study (neutropenia or 
leukocytopenia = 90%) with corresponding infection rates 
of 23%. Recently the same authors reported the results in a 
larger group of B-CLL patients receiving as initial therapy 
the same schedule of treatment using mitoxantrone 6 mg/m2. 
The OR, MRD-negative CR, MRD-positive CR, nodular PR 
(nPR), and PR rates were 90%, 26%, 38%, 14%, and 12%, 
respectively. Median response duration was 37 months. 
Patients with del(17p) failed to attain CR. Patients achiev-
ing MRD-negative CR had a longer response duration and 
OS than patients with an inferior response. Low serum LDH 
levels, low ZAP-70 expression, and mutated IgV(H) genes 
predicted longer response duration.66
Comparable results to FCM regimen have been obtained 
with the combination of FAMP, mitoxantrone, ara-C and 
dexamethasone (FAND) in previously treated patients (OR 
70%, CR 60%), Although severe neutropenia episodes 
occurred in 69% of courses, major infections were seen in 
only 12% of these courses. This low incidence is probably 
explained by the infection prophylaxis with ﬂ  uconazole, 
acyclovir, trimethoprim/sulfamethazole and G-CSF.67
FAMP has also been investigated in combination with 
other chemotherapeutic agents. The majority of these studies 
were small, with less than 50 enrolled patients.
Disappointing results were achieved when FAMP was 
combined with doxorubicin (with or without prednisone) 
with an OR rate of 55% and a CR rate of only 3%.68
Higher response rate was reported in untreated and 
pre-treated patients receiving FAMP associated to epirubicin 
in a phase II study.69
In a phase III, randomized trial, FAMP was compared 
with FAMP plus epirubicin in the same setting.70 Preliminary 
results in 150 patients showed that the combination achieves 
statistically higher response rates and longer duration of event 
free survival; however this does not translate in a statistically 
signiﬁ  cant OS beneﬁ  t.
FAMP with ara-C with 
or without cisplatin
FAMP has also been tested in association with ara-C yielding 
an OR rate of 5% in FAMP refractory patients.71 The addition 
of cisplatin to this regimen improved the OR slightly to 19% 
in a phase II study of 41 pre-treated patients. Notably, the 
combination of FAMP with ara-C or cisplatin was associated 
with particularly high toxicities in terms of cytopenia and 
myelosuppression.72
FAMP and non-chemotherapeutic agents
In the last 2 years the FAMP plus CTX schedule has also 
been tested in association with new non-chemotherapeutic 
drugs resulting previously effective in the treatment of other 
hematological malignancies.
As expression of Bcl-2 protein is associated with che-
motherapy resistance and decreased survival in B-CLL, 
O’Brien et al evaluated whether oblimersen, antisense oli-
gonucleotides would improve response to FC chemotherapy 
in patients with relapsed or refractory B-CLL.
Two hundred and forty-one patients receiving at least 
one prior FAMP-containing regimen were randomly 
assigned to 28-day cycles of FAMP 25 mg/m2/d plus CTX 
250 mg/m2/d administered iv for 3 days with or without 
oblimersen 3 mg/kg/d as a 7-day continuous iv infusion 
(beginning 4 days before chemotherapy) for up to 6 cycles.
CR/nPR rates were signiﬁ  cantly higher in the oblimersen 
arm (17% vs 7%) and achievement of CR/nPR was correlated 
with both an extended time to progression and survival. In 
patients who remained sensitive to FAMP, oblimersen was 
associated with a 4-fold increase in the CR/nPR rate and a 
signiﬁ  cant survival beneﬁ  t.73
Thalidomide has been shown to inhibit production of 
TNF-alpha. Elevated levels of TNF-alpha have been associ-
ated with progressive disease in patients with B-CLL. Chanan 
Khan et al conducted a phase 1/2 clinical trial to determine 
the safety and efﬁ  cacy of combining thalidomide with FAMP 
in patients with treatment-naïve B-CLL. Patients received 
6 months of continuous daily thalidomide with standard 
monthly doses of FAMP. Three dose levels of thalidomide 
(100, 200, and 300 mg) were studied. Thirteen patients were 
enrolled in the phase 1 component of the study. Dose-limiting 
toxicity was not reached. OR rate was 100% with 55% of 
patients achieving CR. At a median follow-up of 15 months 
none of the patients had had a relapse and the median time to 
disease progression had not yet been reached. Responses were 
noted at all dose levels.74 Disappointing results have been 
reported in a small Italian study in which 5 pre-treated B-CLL Therapeutics and Clinical Risk Management 2009:5 196
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patients were enrolled. Four patients had to be withdrawn 
from the study due to disease progression in 3 cases while a 
severe neurological toxicity was detected in 1 patient.75
FAMP in combination 
with monoclonal antibodies
The emergence of monoclonal antibodies has expanded the pos-
sibilities and strategies for therapy in patients with B-CLL.
There are several reasons for combining chemotherapy 
with monoclonal antibodies. First, there is little overlapping 
toxicity. Second, chemotherapy and monoclonal antibodies 
cause cell death by different mechanisms, and B-CLL cells 
that are resistant to one mechanism of cell killing may be 
susceptible to the other. Third, there is preclinical evidence 
to suggest that chemotherapy and monoclonal antibodies 
may act in a synergistic manner. Rituximab is a chimeric 
monoclonal antibody that binds to CD20 and is currently 
approved for the treatment of patients with relapsed low-
grade lymphoma. Alemtuzumab is an anti-CD52 antibody 
approved for B-CLL patients who have failed prior therapy 
with FAMP. More recently FDA granted regular approval 
and expanded labeling for alemtuzumab as single-agent 
treatment for B-CLL.
Rituximab has limited activity as a single agent in B-CLL, 
with reported OR rates ranging from 7% to 35% in relapsed 
patients.76,77 Dose intensiﬁ  cation strategies have been used, 
with higher response rates achieved. However, the majority 
of responses were partial and of brief duration.78
Because of these ﬁ  ndings, rituximab is more often used 
in combination with other chemotherapeutic agents, such as 
FAMP or FAMP plus CTX.79–81
Cancer and Leukemia Group B (CALGB) and the US 
Intergroup investigated in multicenter phase 2 trial (CALGB 
9712) safety and efﬁ  cacy of a immuno-chemotherapeutic 
regimen combining FAMP and rituximab (FR) in treatment-
naive B-CLL. Patients were randomized to receive either 
6 courses of FAMP (one course every 28 days) concurrently 
with rituximab followed 2 months later by 4-weekly doses 
of rituximab for consolidation therapy or sequential FAMP 
alone followed 2 months later by rituximab consolidation 
therapy. In this study rituximab administered concur-
rently with FAMP in previously untreated B-CLL patients 
demonstrates marked clinical efﬁ  cacy in terms of OR (90% 
vs 77%) and CR (47% vs 28%) rates and acceptable toxicity. 
However no differences were detected in term of PFS and 
OS between the two arms.79
The same authors retrospectively compared efﬁ  cacy data 
of the CALGB 9712 study with the CALGB 9011 study that 
compared FAMP as single agent to CHL. In multivariate 
analyses controlling for pre-treatment characteristics, the 
patients receiving FAMP and rituximab had a signiﬁ  cantly 
better PFS and OS than patients receiving FAMP therapy. 
Two-year PFS probabilities were 0.67 vs 0.45, and 2-year 
OS probabilities were 0.93 vs 0.81. Infectious toxicity was 
similar between the two treatment approaches.82 These 
comparative data are retrospective and could be confounded 
by differences in supportive care or dissimilar enrolment of 
genetic subsets on each trial.
A multivariate analysis examining the type of treatment 
(addition or not of rituximab) and other pre-treatment clini-
cal and laboratory features demonstrated that inclusion of 
rituximab was as good as or better than leukocytosis and age 
at predicting PFS and OS.82
More recently the M.D. Anderson Cancer Group pub-
lished results obtained with the combination of FAMP, CTX 
and rituximab (FCR) in previously treated B-CLL patients.
Treatment consisted of rituximab 375 mg/m2 day 1 of 
course 1 and 500 mg/m2 day 1 of courses 2 to 6; FAMP 
25 mg/m2/d days 2 to 4 of course 1 and days 1 to 3 of courses 
2 to 6; and CTX 250 mg/m2/d days 2 to 4 of course 1 and 
days 1 to 3 of courses 2 to 6. Courses were repeated every 
4 weeks. CR was achieved in 25% of 177 patients enrolled, 
with an OR rate of 73%. Molecular remission was achieved 
in a third of patients who obtained CR.80
Table 4 Results of clinical trials on B-CLL with ﬂ  udarabine with ara-C with or without cisplatin
References Comp 
study
No of evaluable 
pts
Prior 
therapy
Treatement regimen Clinical response Survival/duration 
of response
CR (%) OR (%)
FAMP + ara-C
Gandhi et al71
no 15 yes FAMP 30 mg/m2 d1 + ara-C 
500–1000 mg/m2 d1 q 4 wk
0 5 9 mo median OS
FAMP + ara-C + Cis
Giles et al72
no 41 yes FAMP 30 mg/m2 d4 + Cis 25 mg/m2 
d1–4 ± ara-C 500 mg/m2 d4 q 4 wk
0 19 6 mo median OS
Abbreviations: Comp, comparative; CR, complete remission; OR, overall response; OS, overall survival; FAMP, ﬂ  udarabine; ara-C, cytarabine; Cis, cisplatin; d, days; mo, months; 
wk, weeks; q, every; iv, intravenous; os, oral.Therapeutics and Clinical Risk Management 2009:5 198
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Keating et al81 tested FCR schedule in 224 previously 
untreated B-CLL patients. Results and safety were historically 
compared with the previously reported data on a group of 
patients treated with FC.57 The OR and CR rates were 95% and 
70% respectively. The CR rate compared favorably with that 
achieved in the historical experience with FC (35% vs 70%), 
while no differences were detected in OR rate (88% vs 95%). 
Two thirds of patients, receiving FCR schedule, evaluated 
with two-color ﬂ  ow cytometry, had less than 1% CD5+/CD19+ 
coexpressing cells in bone marrow after therapy. Recently the 
authors published an update of long-term results reporting 
a 6-year overall and failure-free survival of 77% and 51%, 
respectively. Median time to progression was 80 months.
Pre-treatment characteristics independently associated 
with inferior response were age 70 years or older (14% of 
patients), beta2-microglobulin twice the upper limit of nor-
mal (2N) or more (43% of patients), white cell count 150 × 
109/L or more (17% of patients), abnormal chromosome 17 
(4% of patients), and LDH 2N or more (2% of patients). No 
pre-treatment characteristic was independently associated 
with decreased CR duration.83
Recently the same authors reported no signiﬁ  cant impact 
of the mutational status on the CR rate and on long-term 
survival in patients treated with FCR. However in patients 
with unmutated IgVH a shorter remission duration was 
observed.84
Interestingly in a multivariate analysis of patients receiv-
ing FAMP-based therapy at M.D. Anderson Cancer Center 
Group, FCR therapy emerged as the strongest independent 
determinant of survival.83
In order to validate the observation of a single center study 
that FCR combination improved the outcome of untreated 
B-CLL patients the GCLLSG initiated a multicenter, 
multinational phase III trial to evaluate the efﬁ  cacy and 
tolerability of FCR vs FC as ﬁ  rst-line treatment of patients 
with advanced B-CLL.
In this study 817 patients were enrolled between July 
2003 and March 2006. After a median observation time of 
25.5 months, 761 patients (FCR 390; FC 371) were evalu-
able for response and 787 patients (FCR 400; FC 387) for 
PFS and all for OS. The OR and CR rates were signiﬁ  cantly 
higher in the FCR arm (95% and 52%) than in FC (88% and 
27%). PFS was 76.6% at 2 years in the FCR arm and 62.3% 
in the FC arm with a trend for an increased OS rate in the 
FCR arm (91% vs 88% at 2 years).85
The major toxicity related to FCR treatment was grade 
3/4 neutropenia while persistent cytopenia following 
completion of therapy and lasting more than 3 months was 
reported in 19% of patients treated. However, following 
recovery of blood counts, recurrent late cytopenia episodes 
occurred in 28% of cases, predominantly during the ﬁ  rst 
year of remission, with 1 and 6 year incidences of 18% and 
23%, respectively.83 One approach to decrease neutropenia 
without compromising efﬁ  cacy could be by reducing the 
doses of FAMP and CTX and increasing the cumulative 
dose of rituximab. Foon et al conducted a phase II study 
for previously untreated advanced B-CLL patients using a 
so-called FCR-Lite schedule (FAMP 20 mg/m2/d days 1–3, 
CTX 150 mg/m2/d days 1–3, rituximab 500 mg/m2/d days 1 
and days 14 every 4 weeks; maintenance rituximab 500 mg/m2 
every 3 months until progression).
Fifty patients were enrolled to receive treatment and 
48 were evaluable for response. Among them CR rate was 
77%, PR rate was 23% with an OR rate of 100%. Patients 
who achieved CR were tested by two-color ﬂ  ow cytometry 
and 97% of patients had  1% CD5+/CD19+ cells in their 
bone marrow after therapy. This experience suggests that 
FCR-Lite is highly effective with considerably less grade 
3/4 neutropenia than standard FCR. Complete responders 
had no detectable CD5+/CD19+ cells in their bone marrow 
following FCR-Lite.86
As previously mentioned a synergistic effect has been 
demonstrated between FAMP, ara-C and cisplatin.72 The 
M.D. Anderson Cancer Group explored the efﬁ  cacy of 
FAMP plus rituximab when associated to oxaliplatin and 
ara-C in OFAR regimen that consisted of increasing doses 
of oxaliplatin (17.5, 20, or 25 mg/m2/d on days 1–4, phase I), 
FAMP 30 mg/m2/d on days 2 to 3, ara-C 1 g/m2/d on days 2 
to 3, rituximab 375 mg/m2 on day 3 of cycle 1 and day 1 of 
subsequent cycles, and pegﬁ  lgrastim 6 mg on day 6, every 
4 weeks for a maximum of 6 courses.
In a phase I–II trial 50 patients were treated (20 patients 
had Richter’s syndrome, and 30 had a FAMP refractory 
B-CLL) with OFAR schedule. This regimen was highly 
active with an OR rate of 50% in Richter’s syndrome and of 
33% in FAMP-refractory B-CLL. Satisfactory response was 
also achieved in 7 of the 20 patients with 17p deletion (35%) 
and in 2 of 7 patients with 11q deletion (29%).87
Based upon the excellent previously mentioned results 
obtained with FCM,88 the same group of authors have built 
up a new chemoimmunotherapy combination with rituximab 
plus FCM (R-FCM). In a phase II study 72 patients under the 
age of 70 with active B-CLL according to NCI and IWCLL 
criteria received R-FCM regimen as initial treatment fol-
lowed by a maintenance therapy phase consisting of ritux-
imab every 3 months for 2 years. Although based on two Therapeutics and Clinical Risk Management 2009:5 199
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different phase II studies that preclude a completely valid 
statistical comparison, the CR rate obtained with R-FCM 
(82%, of which 46% MRD-negative CR) favorably compares 
with that achieved with FCM (CR 64%, MRD-negative CRs 
38%). In summary the 82% CR rate obtained with R-FCM 
is among the highest ever reported for any form of therapy 
for B-CLL and treatment toxicity was acceptable and man-
ageable.88 Based on these results, R-FCM warrants further 
investigation, particularly in randomized clinical trials.
In the scene of monoclonal antibodies available 
for B-CLL treatment alemtuzumab has certainly shown supe-
rior activity when compared with rituximab as monotherapy. 
In addition, alemtuzumab is most effective in reducing leu-
kemia counts and bone marrow disease and less effective in 
shrinking bulky lymphadenopathy. Alemtuzumab has been 
studied in FAMP refractory B-CLL patients,89 in previously 
untreated patients,90 in patients with MRD persistence after 
FAMP-based regimen,91,92 and concurrent with FAMP93,94 
and rituximab.95,96 Apart from the infusional reaction related 
to iv administration of alemtuzumab, the development of 
opportunistic infections are reported. Antibacterial and 
antiviral prophylaxis is recommended in all patients receiv-
ing alemtuzumab therapy.
The ﬁ  rst experiment was conducted by Kennedy et al who 
treated 6 patients with B-CLL who were refractory to both 
alemtuzumab and FAMP used as single agents, and found that 
5 of 6 patients responded to combination therapy, including 
1 CR. However, long-term follow-up is not yet available. 
The toxicity of this regimen was acceptable, with none of 
the patients developing serious infections.93
Elter et al extended these observations to a larger cohort 
of patients with relapsed or refractory B-CLL. Thirty-six 
patients were treated with alemtuzumab 30 mg/d iv and 
FAMP 30 mg/m2/d iv on 3 consecutive days every 28 days 
for a total of 6 cycles (4 cycles in the ﬁ  rst 14 patients).
The OR and CR rates were 83% and 30% respectively. 
The median OS was 35.6 months for all patients, with a time 
to progression of 22 months in patients who achieved a CR 
and 13 months for patients who achieved a PR. The treatment 
was well tolerated with acceptable infectious morbidity.94 
Based upon these results, a phase III study comparing FAMP 
alone to FAMP plus alemtuzumab is currently underway in 
Europe.
Subsequently the M.D. Anderson group explored combi-
nation of alemtuzumab plus FAMP with CTX and rituximab 
with the goal of improving CR rate and eliminating MRD. 
Wierda et al reported the preliminary results of a phase II 
trial in which 31 patients with pre-treated B-CLL were treated 
with CTX (250 mg/m2/d days 3–5), FAMP (25 mg/m2/d days 
3–5 i.v.) alemtuzumab (30 mg day 1, 3, 5) and rituximab 
(500 mg/m2 day 2), every 28 days for 6 cycles. Twenty-one 
patients were evaluable for response and after a median 
number of 3 cycles (range 1–6) the OR rate was 52%, with 
3 patients achieving a CR (14%) and 8 patients achieving a 
PR (38%). CMV reactivation was noted in 5 of 21 patients.95 
Based upon these results, CFAR regimen was tested in a 
larger phase II study in patients with high risk and NCI 
indication for frontline therapy. OR and CR rates were 95% 
and 71% respectively. All patients in CR and nPR and 3 of 
4 in PR were free of disease in the bone marrow by three-
color ﬂ  ow cytometry. There was no signiﬁ  cant correlation 
between CR or OR and Rai stage, IgVH mutation status, 
FISH status, or ZAP70 or CD38 expression. Grade 3 or 4 
neutropenia and thrombocytopenia were seen in 27% and 
7% of courses respectively and major infections were seen 
in 2% of courses.96
Montillo et al reported interesting results combining 
FAMP plus alemtuzumab with CTX (FCC schedule) in 
a phase II study in patients with B-CLL with relapsed 
or refractory disease after at least one line of treatment. 
Subcutaneous route of administration of alemtuzumab 
was adopted in this trial. The FCC regimen consisted of 
FAMP 40 mg/m2/d oral days 1–3, CTX 250 mg/m2/d oral 
days 1–3 and alemtuzumab 10 to 20 mg subcutaneous days 
1–3. This combination was repeated on day 29 for up to 6 
cycles. Among the 25 patients enrolled OR rate was 79%, 
with 37% patients achieving CR. Grade III-IV neutropenia 
episodes were observed in 43% of the administered courses 
while grade III-IV thrombocytopenia episodes were detected 
only in 8% of cycles. Four major infections were recorded.97 
Similar OR and CR rate have been obtained by Elter with the 
same combination.98 Two phase III studies comparing FC to 
FC plus alemtuzumab and FCR to FC plus alemtuzumab are 
currently ongoing in Europe by HOVON and GOELAMS 
respectively.
Another monoclonal antibody tested in B-CLL is Lumil-
iximab an anti-CD23 with human IgG1 constant regions and 
macaque variable regions.
Preclinical data demonstrated that lumiliximab enhanced 
both FAMP- and rituximab- mediated apoptosis in B-CLL 
cells.
Preliminary results of phase 1/2, open-label, dose-escalation, 
multicenter study evaluating lumiliximab + FCR for relapsed 
CD23+ B-CLL have been reported. Treatment has been 
completed and follow-up is ongoing. Thirty-one patients 
received either 375 mg/m2 or 500 mg/m2 of lumiliximab in Therapeutics and Clinical Risk Management 2009:5 200
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combination with a 28-day cycle of FCR for up to 6 cycles. 
The most common adverse events included nausea (77%), 
pyrexia (61%), chills (55%), neutropenia (55%), and fatigue 
(48%). Twenty patients (65%) experienced a Grade III or IV 
event. CR was achieved in 48% of patients with an OR rate 
of 71%. A comparison with data reported using FCR alone 
in relapsed or refractory B-CLL80 demonstrated that Lumil-
iximab + FCR has an acceptable safety proﬁ  le. Moreover, it 
does not appear to increase the toxicity (including myelosup-
pression) of the FCR regimen, and compares favorably with 
the CR rate of the FCR regimen alone.99
Studies testing FAMP combined with monoclonal anti-
bodies are listed in Table 5.
FAMP in allogeneic stem cell 
transplantation
Allogeneic stem cell transplantation (alloSCT) is used for 
the treatment of various hematological malignancies. The 
standard approach has involved the use of a conditioning 
regimen, comprising myeloablative doses of chemo-radio-
therapy, to eradicate the underlying malignancy and eliminate 
the host’s bone marrow in preparation for allogeneic graft, 
which functions primarily as a bone marrow rescue. More 
recently it has been suggested that the complete eradication 
of tumor cells is largely mediated by an immune-mediated 
destruction of malignant cells by donor lymphocytes, termed 
the graft-versus-leukemia (GVL) or graft-vs-tumor (GVT) 
effect. Replacing high-dose myeloablative therapy with a 
nonmyeloablative conditioning regimen would allow treat-
ment of those patients who are too old or medically unﬁ  t to 
qualify for conventional alloSCT.100 The aim of non-myeloab-
lative alloSCT is to use a low intensity preparative regimen to 
induce sufﬁ  cient immunosuppression in the recipient to allow 
engraftment of allogeneic stem cells to prevent graft rejec-
tion. The non-myeloablative regimen does not completely 
eliminate host-derived cells, but over a period of time allo-
geneic lymphocytes act to eliminate residual hematopoietic 
and malignant cells. The drugs used in non-myeloablative 
conditioning regimens are generally chosen because they 
have some activity against the target malignancy and also 
provide sufﬁ  cient immunosuppression to allow engraftment 
of allogeneic stem cells.
FAMP has been widely used in non-myeloablative con-
ditioning regimens because of its immunosuppressive and 
antitumor activity. FAMP is often combined with a variety 
of other cytotoxic agents, such as melphalan, CTX, ara-C and 
busulfan, or with low-dose total body irradiation, with the aim 
of inducing enough immunosuppression to allow successful 
engraftment and to exert some pretransplant anti-tumor 
activity. Non-myeloablative combination regimens with 
FAMP and other cytotoxic agents have been used in patients 
with various hematological diseases, including AML, 
chronic myeloid leukemia (CML), B-CLL, non-Hodgkin’s 
lymphoma (NHL), Hodgkin’s disease (HD), acute lymphoid 
leukemia (ALL) and multiple myeloma.101–104 The objective 
of achieving donor engraftment using a FAMP-based non-
myeloablative conditioning regimen was achieved in all the 
studies reviewed. More recently, the addition of the mono-
clonal antibody alemtuzumab to a FAMP-based protocol has 
been shown to reduce the incidence of GVHD, warranting 
further investigation in a randomized trial.105
The main studies using FAMP-based regimen as non-
myeloablative conditioning in B-CLL patients are reported 
in Table 6
Adverse events
The most frequent adverse events associated with standard-
dose iv FAMP regimens are myelosuppression (neutropenia, 
thrombocytopenia and anemia) and infection (typically 
respiratory tract infections and fever). Myelosuppression is 
the major dose-limiting adverse effect. NCI grade IV hema-
tological toxicity was reported in 43% of patients receiving 
FAMP monotherapy for advanced-stage refractory B-CLL.33 
In large-scale randomized studies, neutropenia, thrombocy-
topenia and anemia (WHO grade III/IV) occurred in 19%, 
14% and 7% of FAMP treatment cycles, respectively, and 
affected 38, 15% and 18% of patients, respectively, dur-
ing the ﬁ  rst 6 treatment cycles.40 Severe (Grade III or IV) 
neutropenia tended to be more frequent with FAMP than 
with CHL (27% vs 19%).Treatment with FAMP leads to a 
decrease in the CD4+/CD8+ ratio for an extensive period of 
time, exceeding even 24 months.106 In consequence, infec-
tions, including opportunistic ones, are frequent events 
and infections with fatal outcome have been reported.107,108 
FAMP-associated infection affects approximately 5% of 
patients with B-CLL,41 is accompanied by a sustained fall 
in T-cell numbers,44 and is exacerbated by coadministration 
of prednisone.109 Prolonged immunosuppression related to 
FAMP treatment may increase the risk of second malignan-
cies. A retrospective analysis performed by Cheson et al in 
which they compared secondary tumours in B-CLL patients 
treated with FAMP, shows that this agent does not increase 
the risk of secondary neoplasms.110
Also MDS and secondary AML (sAML) are rarely 
reported following FAMP monotherapy and no such cases 
were reported in 3 large cohorts of patients receiving FAMP Therapeutics and Clinical Risk Management 2009:5 201
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as initial therapy for B-CLL13,40,41 and only a single case was 
recorded among 724 patients receiving FAMP as salvage 
therapy for B-CLL.110 However, the combination of FAMP 
with CTX or other DNA damaging agents or following inten-
siﬁ  cation with transplant procedure may increase the risk of 
MDS/sAML due to synergistic effects in the induction and 
inhibition of DNA damage.111–113
Some reports suggest that FAMP may induce autoimmune 
hemolytic anemia (AIHA) in patients with B-CLL despite 
the reduction in leukemic clone.114 In the study performed 
by French Cooperative Group newly occuring AIHA was 
observed in only 2 patients treated with FAMP.40 Leporrier 
et al reported true AIHA only in 3% of the patients treated 
with CHOP, 1.5% treated with CAP and 1.5% treated with 
FAMP.41 Also in the LRFCLL4 trial the frequency of AIHA 
at completion of treatment was no different between CHL 
(12%) and FAMP (11%), and the lowest rate was noted after 
FAMP plus CTX administration (5%).62
These ﬁ  ndings suggest that FAMP plus CTX might 
have a protective effect, supporting similar observations 
of a study by the GCLLSG.59 Although, the results of the 
prospective multicenter randomized studies do not sup-
port the conclusion that the risk of AIHA is higher in the 
B-CLL patients treated with FAMP than in patients treated 
with CHL or other alkylating agents based regimens, the 
AIHA after FAMP could be more severe and more difﬁ  cult 
to treat as suggested by the fatal events observed in the 
LRFCLL4 trial.62
Pure red cell aplasia (PRCA) occurs in approximately 
5% of B-CLL patients, most often in the course of disease, 
but also at presentation. The inﬂ  uence of FAMP on PRCA in 
patients with B-CLL has not been deﬁ  nitely deﬁ  ned yet.
The inﬂ  uence of prior treatment on the development of 
an aggressive NHL during the course of B-CLL (Richter’s 
syndrome) is unclear. Cheson et al found 18 (3.0%) patients 
with NHL among 595 patients treated with FAMP.110 In a 
retrospective analysis of 1487 B-CLL patients Richter’s syn-
drome was observed in 1% of cases in a group treated with 
cladribine, 0.9% in a group treated with alkylating agents and 
0.6% in a group treated with cladribine + alkylating agents.115 
The estimation of real incidence of Richter’s syndrome in 
patients treated with purine analogs needs further observation 
and longer follow-up.
Although there are reports documenting that FAMP 
impairs PBSC mobilization, this is still a much-discussed 
issue. It has been shown that other factors may affect the 
ability to mobilize stem cells: the number of prior therapeutic 
regimens, the disease stage at the time of mobilization, the Therapeutics and Clinical Risk Management 2009:5 203
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quality of response to FAMP. An early report from the 
EBMT indicated that FAMP did not impair progenitor cell 
mobilization, although better results were obtained early in 
the course of the disease and after two months from the last 
cycle of treatment.116 However, 2 reports have identiﬁ  ed that 
prior FAMP therapy in patients with lymphoprolipherative 
disease may be associated with difﬁ  culties in obtaining 
adequate progenitor cell numbers.117,118 It is possible that 
more effective mobilization strategies, and also more inten-
sive cytoreductive therapy to achieve better disease control 
prior to attempting mobilization might help yield an adequate 
harvest in an even greater proportion of patients.119
Conclusion
The increased knowledge of the biological and clinical 
features of B-CLL has been mirrored by the development 
of therapeutic agents that are more active than previous 
approaches. In this setting, FAMP has made the most sig-
niﬁ  cant impact on how we manage B-CLL today. Compared 
to traditional strategies, FAMP has improved remission rates 
and lengthened response duration, and has rapidly become 
established as the gold standard of care in B-CLL.
Furthermore FAMP has been shown to have a synergistic/
biochemical modulating effect, with other chemotherapeu-
tic agents and, more recently, with monoclonal antibodies. 
Thus, FAMP serves as a paradigm for the development of 
anticancer treatment with rational combinations in modern 
therapeutic regimens.
The data reviewed indicate that FAMP administered in 
combination regimens may improve quality and rates of 
response, compared with FAMP in monotherapy in both 
pre-treated and untreated B-CLL patients. Although FC 
combination demonstrated exciting results in terms of OR 
and CR rates ranging from 74% to 94% and from 23% to 38% 
respectively, no difference was detected in survival.
Recently, eradication of MRD in B-CLL has been reported 
to be associated with prolonged survival. The development of 
such a wide variety of novel ‘targeted’ therapies for B-CLL 
and in particular of monoclonal antibody promises to make 
the goal of achieving MRD-negative remissions a reality for 
a large proportion of patients. The combination of FAMP/
CTX/mitoxantrone and FAMP combinations with rituximab 
or alemtuzumab, might be promising, since a relevant number 
of complete molecular remissions are achieved with these 
drugs. The precise role of FAMP combinations within the 
overall treatment strategy remains to be determined. How-
ever, it is worth mentioning the results recently reported of 
trial CLL8 GCLLSG suggesting that FCR combination might 
become the new standard ﬁ  rst-line treatment for physically 
ﬁ  t B-CLL patients.
Combination of FAMP with other drugs rather than 
chemotherapeutic agents such as oblimersen or thalidomide 
warrants further investigation.
Increased clinical use of FAMP has highlighted its poten-
tial toxic effects, primarily myelo- and immuno-suppression. 
However, myelosuppression can be managed, even with the 
use of growth factors, and infectious complications can be 
prevented with adequate prophylaxis.
The most recent improvement in FAMP therapy is the 
development of an oral formulation with equivalent efﬁ  -
cacy and tolerability to the iv preparation, coupled with the 
advantage of improved convenience of administration (for 
both patient and physician) and potentially superior cost 
effectiveness.
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